SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: PK who wrote (955)5/11/1998 4:16:00 PM
From: Phil Cressman   of 2135
 
Not so fast! To produce the proteins is going to cost major bucks.
The proteins haven't yet indicated any value and won't for a few years. The best you can hope for is a pharma to kick in dollars for R&D for which they will want to buy shares and obtain marketing rights to proteins. What ENMD will hopefully end up with in 4 or 5 years is a cash flow from royalties if the compounds prove out. During this time they also have to foot a share of the R&D costs. Expect another round of financing and shareholder dilution this year or early next.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News